Amgen Q4 Earnings Call Highlights

Amgen (NASDAQ:AMGN) executives highlighted broad-based growth in 2025 and laid out expectations for continued momentum in ...

Amgen: Strong Mitigation Of LOE Impact, Regulatory Tensions On Tavneos Emerge

Amgen delivered a strong Q4 2025, exceeding revenue and EPS expectations and guiding for 2026 growth despite major loss of ...
Stocktwits on MSN

Amgen CEO teases 2026 as ‘springboard year’ after 14 blockbusters and 18 record products

Amgen’s financial performance was underpinned by strength in its lineup. The company said 14 products generated at least $1 billion each in annual sales, 13 posted double-digit growth, and 18 ...
KXAN

AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.

THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha ® (evolocumab). This follows ...
Seeking Alpha

AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL

THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...
Los Angeles Downtown News

AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL

Repatha was first approved in 2015 and has since been used by more than 6.7 million patients globally. 3,4 Earlier this year, the U.S. Food and Drug Administration broadened the approved use of ...